Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Szpurka AM"'
Autor:
Schöffski P; University Hospitals Leuven, Leuven Cancer Institute, Leuven, Belgium., Bahleda R; Gustave Roussy, Villejuif, France., Wagner AJ; Dana-Farber Cancer Institute, Boston, Massachusetts., Burgess MA; Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania., Junker N; Herlev and Gentofte Hospital, University of Copenhagen, Herlev, Denmark., Chisamore M; Merck & Co., Inc., Rahway, New Jersey., Peterson P; Eli Lilly & Company, Indianapolis, Indiana., Szpurka AM; Eli Lilly & Company, Indianapolis, Indiana., Ceccarelli M; Eli Lilly & Company, Indianapolis, Indiana., Tap WD; Memorial Sloan Kettering Cancer Center, New York, New York.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2023 Sep 01; Vol. 29 (17), pp. 3320-3328.
Autor:
Goldman JW; David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States., Sholl LM; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States., Dacic S; Department of Pathology, Yale School of Medicine, New Haven, CT, United States., Fishbein MC; David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States., Murciano-Goroff YR; Department of Medicine, Memorial Sloan-Kettering Cancer Center New York, NY, United States., Rajaram R; Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, United States., Szymczak S; Loxo@Lilly, Eli Lilly and Company, Warsaw, Poland., Szpurka AM; Loxo@Lilly, Eli Lilly and Company, Indianapolis, IN, United States., Chao BH; Loxo@Lilly, Eli Lilly and Company, New York, NY, United States., Drilon A; Department of Medicine, Memorial Sloan-Kettering Cancer Center New York, NY, United States.; Department of Medicine, Weill Cornell Medical College, New York, NY, United States.
Publikováno v:
Frontiers in oncology [Front Oncol] 2023 May 18; Vol. 13, pp. 1178313. Date of Electronic Publication: 2023 May 18 (Print Publication: 2023).
Autor:
Sweeney CJ; Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Percent IJ; Florida Cancer Specialists and Research Institute/Sarah Cannon Research Institute, Port Charlotte, Florida., Babu S; Fort Wayne Medical Oncology and Hematology, Fort Wayne, Indiana., Cultrera JL; Florida Cancer Specialists/Sarah Cannon Research Institute, Leesburg, Florida., Mehlhaff BA; Oregon Urology Institute, Springfield, Oregon., Goodman OB; Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada., Morris DS; Urology Associates, PC, Nashville, Tennessee., Schnadig ID; Compass Oncology, Tualatin, Oregon., Albany C; Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana., Shore ND; Carolina Urologic Research Center, Myrtle Beach, South Carolina., Sieber PR; Keystone Urology Specialists, Lancaster, Pennsylvania., Guba SC; Eli Lilly and Company, Indianapolis, Indiana., Zhang W; Eli Lilly and Company, Indianapolis, Indiana., Wacheck V; Eli Lilly and Company, Indianapolis, Indiana., Donoho GP; Eli Lilly and Company, Indianapolis, Indiana., Szpurka AM; Eli Lilly and Company, Indianapolis, Indiana., Callies S; Eli Lilly and Company, Indianapolis, Indiana., Lin BK; Eli Lilly and Company, Indianapolis, Indiana., Bendell JC; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2022 Jun 01; Vol. 28 (11), pp. 2237-2247.
Autor:
Hollebecque A; Drug Development Department (DITEP), Gustave Roussy, Villejuif, France. antoine.hollebecque@gustaveroussy.fr., Chung HC; Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of South Korea., de Miguel MJ; START Madrid, HM Sanchinarro Centro Integral Oncológico Clara Campal, Madrid, Spain., Italiano A; Institut Bergonié, Bordeaux, France., Machiels JP; Department of Medical Oncology, Cliniques universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale (Pole MIRO), Institut Roi Albert II, Université catholique de Louvain, Brussels, Belgium., Lin CC; National Taiwan University Hospital, Taipei, Taiwan., Dhani NC; Princess Margaret Cancer Centre, Division of Medical Oncology and Hematology, Toronto, Ontario, Canada., Peeters M; Department of Oncology, Antwerp University Hospital, Edegem, Belgium., Moreno V; START Madrid FJD, Hospital Universitario Fundación Jimenez Diaz, Madrid, Spain., Su WC; National Cheng Kung University Hospital, Taiwan., Chow KH; Eli Lilly and Company, Windlesham, Surrey, United Kingdom., Galvao VR; Eli Lilly and Company, Indianapolis, Indiana., Carlsen M; Eli Lilly and Company, Indianapolis, Indiana., Yu D; Eli Lilly and Company, Indianapolis, Indiana., Szpurka AM; Eli Lilly and Company, Indianapolis, Indiana., Zhao Y; Eli Lilly and Company, Indianapolis, Indiana., Schmidt SL; Eli Lilly and Company, Indianapolis, Indiana., Gandhi L; Eli Lilly and Company, New York, New York., Xu X; Eli Lilly and Company, New York, New York., Bang YJ; Seoul National University College of Medicine, Seoul, Republic of South Korea.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2021 Dec 01; Vol. 27 (23), pp. 6393-6404. Date of Electronic Publication: 2021 Aug 31.
Autor:
Kotecki N; Jules Bordet Institute, Brussels., Vuagnat P; Drug Development Department (DITEP), Gustave Roussy Institute, Villejuif, France., O'Neil BH; Department of Hematology-Oncology, Indiana University Simon Comprehensive Cancer Center.; Eli Lilly and Company., Jalal S; Indiana University School of Medicine, Indianapolis, IN., Rottey S; Ghent University Hospital, Ghent, Belgium., Prenen H; University Hospital Antwerp, Edegem, Belgium., Benhadji KA; Eli Lilly and Company, New York, NY., Xia M; Eli Lilly and Company., Szpurka AM; Eli Lilly and Company., Saha A; Eli Lilly and Company., Wallin J; Eli Lilly and Company, Stockholm, Sweden., Suriyapperuma S; Eli Lilly and Company, Surrey, UK., Galvao VR; Eli Lilly and Company., Geeganage S; Eli Lilly and Company., Doman TN; Eli Lilly and Company., Gandhi L; Eli Lilly and Company, New York, NY., Xu X; Eli Lilly and Company, New York, NY., Bendell J; Sarah Cannon Research Institute Tennessee Oncology, Nashville, TN.
Publikováno v:
Journal of immunotherapy (Hagerstown, Md. : 1997) [J Immunother] 2021 Sep 01; Vol. 44 (7), pp. 264-275.
Autor:
Dowlati A; Department of Medicine Division of Hematology and Oncology, University Hospitals Seidman Cancer Center and Case Western Reserve University, Cleveland, OH, USA., Harvey RD; Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA., Carvajal RD; Department of Medicine, Division of Hematology/Oncology, Columbia University, College of Physicians and Surgeons New York, New York, NY, USA., Hamid O; Department of Hematology/Oncology, The Angeles Clinic and Research Institute, Cedars-Sinai Affiliate, Los Angeles, CA, USA., Klempner SJ; Department of Medicine and Oncology, Massachusetts General Hospital, Boston, MA, USA., Kauh JSW; Medical Oncology, Hutchison MediPharma Inc., Florham Park, NJ, USA., Peterson DA; Eli Lilly and Company, Indianapolis, IN, USA., Yu D; Eli Lilly and Company, Indianapolis, IN, USA., Chapman SC; Eli Lilly and Company, Windlesham, Surrey, UK., Szpurka AM; Eli Lilly and Company, Indianapolis, IN, USA., Carlsen M; Eli Lilly and Company, Indianapolis, IN, USA., Quinlan T; Eli Lilly and Company, Indianapolis, IN, USA., Wesolowski R; Internal Medicine, Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, 1310D Lincoln Tower, 1800 Cannon Drive, Columbus, OH, 43210, USA. Robert.Wesolowski@osumc.edu.
Publikováno v:
Investigational new drugs [Invest New Drugs] 2021 Aug; Vol. 39 (4), pp. 1057-1071. Date of Electronic Publication: 2021 Feb 23.
Autor:
Zauderer MG; Memorial Sloan Kettering Cancer Center, New York, NY, USA. zauderem@mskcc.org.; Taiho Oncology Inc, Princeton, NJ, USA. zauderem@mskcc.org., Alley EW; Cleveland Clinic Florida, Weston, FL, USA., Bendell J; Sarah Cannon Research Institute / Tennessee Oncology, Nashville, TN, USA., Capelletto E; University of Turin, Torino, TO, Italy., Bauer TM; Sarah Cannon Research Institute / Tennessee Oncology, Nashville, TN, USA., Callies S; Eli Lilly and Company, Indianapolis, IN, USA., Szpurka AM; Eli Lilly and Company, Indianapolis, IN, USA., Kang S; Eli Lilly and Company, Indianapolis, IN, USA., Willard MD; Eli Lilly and Company, Indianapolis, IN, USA., Wacheck V; Taiho Oncology Inc, Princeton, NJ, USA.; Eli Lilly and Company, Indianapolis, IN, USA., Varghese AM; Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Publikováno v:
Investigational new drugs [Invest New Drugs] 2021 Aug; Vol. 39 (4), pp. 1081-1088. Date of Electronic Publication: 2021 Mar 04.
Autor:
Hellmann MD; Memorial Sloan Kettering Cancer Center, New York, New York. hellmanm@mskcc.org., Bivi N; Eli Lilly and Company, Indianapolis, Indiana., Calderon B; Eli Lilly and Company, Indianapolis, Indiana., Shimizu T; National Cancer Center Hospital, Chuo-Ku, Tokyo, Japan., Delafontaine B; Ghent University Hospital, Gent, Belgium., Liu ZT; Eli Lilly and Company, Indianapolis, Indiana., Szpurka AM; Eli Lilly and Company, Indianapolis, Indiana., Copeland V; Eli Lilly and Company, Indianapolis, Indiana., Hodi FS; Dana Farber Cancer Institute, Boston, Massachusetts., Rottey S; Ghent University Hospital, Gent, Belgium., Aftimos P; Clinical Trials Conduct Unit, Institut Jules Bordet - Université Libre de Bruxelles, Brussels, Belgium., Piao Y; Eli Lilly Japan K. K., Kobe, Japan., Gandhi L; Dana Farber Cancer Institute, Boston, Massachusetts., Galvao VR; Eli Lilly and Company, Indianapolis, Indiana., Leow CC; Eli Lilly and Company, Indianapolis, Indiana., Doi T; National Cancer Center Hospital East, Chiba, Japan.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2021 May 15; Vol. 27 (10), pp. 2773-2781. Date of Electronic Publication: 2021 Jan 13.
Autor:
Harding JJ; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York. hardinj1@mskcc.org., Moreno V; START Madrid-FJD, Hospital Fundación Jiménez Díaz, Madrid, Spain., Bang YJ; Seoul National University College of Medicine, Seoul, Republic of South Korea., Hong MH; Yonsei Cancer Center, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of South Korea., Patnaik A; South Texas Accelerated Research Therapeutics, San Antonio, Texas., Trigo J; Medical Oncology Department, Hospital Universitario Virgen de la Victoria, Malaga, Spain., Szpurka AM; Eli Lilly and Company, Indianapolis, Indiana., Yamamoto N; National Cancer Center Hospital, Tokyo, Japan., Doi T; Department of Experimental Therapeutics, National Cancer Center Hospital East, Chiba, Japan., Fu S; Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, Texas., Calderon B; Eli Lilly and Company, Indianapolis, Indiana., Velez de Mendizabal N; Eli Lilly and Company, Indianapolis, Indiana., Calvo E; START Madrid, Centro Integral Oncológico Clara Campal, Madrid, Spain., Yu D; Eli Lilly and Company, Indianapolis, Indiana., Gandhi L; Dana Farber Cancer Institute, Boston, Massachusetts., Liu ZT; Eli Lilly and Company, Indianapolis, Indiana., Galvao VR; Eli Lilly and Company, Indianapolis, Indiana., Leow CC; Eli Lilly and Company, New York, New York., de Miguel MJ; START Madrid, Centro Integral Oncológico Clara Campal, Madrid, Spain.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2021 Apr 15; Vol. 27 (8), pp. 2168-2178. Date of Electronic Publication: 2021 Jan 29.
Autor:
Patnaik A; South Texas Accelerated Research Therapeutics, San Antonio, Texas. amita.patnaik@startsa.com., Yap TA; Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, Texas., Chung HC; Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of South Korea., de Miguel MJ; START Madrid, Madrid, Spain., Bang YJ; Seoul National University College of Medicine, Seoul, Republic of South Korea., Lin CC; National Taiwan University Hospital, Taipei, Taiwan., Su WC; National Cheng Kung University Hospital, Tainan, Taiwan., Italiano A; Institut Bergonié, Bordeaux, France., Chow KH; Eli Lilly and Company, Windlesham, Surrey, United Kingdom., Szpurka AM; Eli Lilly and Company, Indianapolis, Indiana., Yu D; Eli Lilly and Company, Indianapolis, Indiana., Zhao Y; Eli Lilly and Company, Indianapolis, Indiana., Carlsen M; Eli Lilly and Company, Indianapolis, Indiana., Schmidt S; Eli Lilly and Company, Indianapolis, Indiana., Vangerow B; Eli Lilly and Company, Indianapolis, Indiana., Gandhi L; Eli Lilly and Company, New York, New York., Xu X; Eli Lilly and Company, New York, New York., Bendell J; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2021 Mar 01; Vol. 27 (5), pp. 1267-1277. Date of Electronic Publication: 2020 Nov 23.